Lenvatinib plus pembrolizumab compared to carboplatin plus paclitaxel for carboplatin and paclitaxel pretreated, recurrent, or advanced endometrial cancer

Lenvatinib plus pembrolizumab compared to carboplatin plus paclitaxel for carboplatin and paclitaxel pretreated, recurrent, or advanced endometrial cancer

Abstract Background Lenvatinib plus pembrolizumab has demonstrated improved survival compared with doxorubicin or paclitaxel monotherapy in patients with advanced or recurrent endometrial cancers (ECs). However, response rates to monotherapy are poor in recurrent settings. Herein, we performed a ret...

Full description

Saved in:
Bibliographic Details
Main Authors: Shao-Jing Wang, Lou Sun, Yu-Hsiang Shih, Ting-Fang Lu, Yen-Fu Chen, Shih-Tien Hsu, Chin-Ku Liu, Sheau-Feng Hwang, Jem-Kun Chen, Hsin-Hua Chen, Chien-Hsing Lu
Format: Article
Language:English
Published: BMC 2025-03-01
Series:BMC Medicine
Subjects:
Endometrial cancer
Lenvatinib
Pembrolizumab
Carboplatin
Paclitaxel
Doxorubicin
Online Access:https://doi.org/10.1186/s12916-025-03989-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items